Company Profile

LaserGen Inc
Profile last edited on: 6/27/18      CAGE: 47M22      UEI:

Business Identifier: Nucleotide chemistry and genomic sequencing
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8052 El Rio Street
Houston, TX 77054
   (713) 747-3380
Location: Single
Congr. District: 09
County: Harris

Public Profile

In April 2018, LaserGen, Inc. was aquired by Agilent Technologies Inc (NYSE: A) for $105M. LaserGen, Inc. is a biotechnology company focused on commercializing novel technologies in nucleotide chemistry and next-generation genomic sequencing. The firm has strong research collaborations with Baylor College of Medicine and Rice University. Through collaboration, technology, and license agreements, LaserGen has begun developing a proprietary platform for DNA sequencing of whole genomes that will (1) provide new capabilities, significant cost savings, and efficiency gains for the research market and (2) provide rapid, portable diagnoses of common diseases in the clinical setting. The technology platforms rest on development of novel fluorescent nucleotides for application of a sequencing-by-synthesis (SBS) method and development of a novel method of fluorescent detection using Pulsed Multiline Excitation (PME). Lasergen’s key technology, Lightning Terminators™, provides unique photocleavable terminator chemistry with faster reaction kinetics and robust cleavage properties. The benefits extend beyond their original design in enhanced next-generation sequencing to include applications in genomics, proteomics and transcriptomi

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 DHA $150,000
Project Title: Feasibility Study to Explore NGS technologies for Pathogen Identification
2005 1 NIH $534,854
Project Title: Development of a portable PME DNA sequencer
2005 1 NIH $289,689
Project Title: Synthesis of Fluorobase Nucleotides for DNS Sequencing
2004 1 NIH $148,397
Project Title: Fluorescent, Photolabile Terminators for DNA Sequencing
2004 2 NIH $423,461
Project Title: Screening Tag Pol I Variants using 3'-O- Modified-dNTPs

Key People / Management

  Mimi Healy -- CEO

  Michael L Metzker -- Founder, Former President and CEO

  Stacie Frye -- VP, Commercial Operations

  Claudia Hertzog -- Director of Strategy and Analytics

  David Hertzog -- Vice President, Business Development

  Vladislav A Litosh

  Matthew Mahindaratne

  Cheryl Smith -- Operations Manager

  Weidong Wu -- Director of Chemistry